PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$143.00
−0.49%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $2.43
- Revenue estimate
- $240.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $2.29
- EPS estimate
- $2.27
- Revenue actual
- $213.5M
- Revenue estimate
- $212.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +825.9%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $179
- PT range
- $170 – $190
- Analysts
- 7
7 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $2.27 | $2.29 | Beat 0.88% | $213.5M |
| May 5, 2026 | -$0.65 | $0.05 | Beat 107.69% | $56.4M |
| Nov 6, 2025 | -$0.59 | -$0.62 | Miss -5.08% | $4.7M |
| Feb 21, 2025 | $0.06 | $1.98 | Beat 3200.00% | $170.6M |
| Nov 7, 2024 | -$0.59 | -$0.54 | Beat 8.47% | $4.7M |
| Feb 27, 2024 | $0.03 | $0.44 | Beat 1425.13% | $60.0M |
| Nov 2, 2023 | -$0.68 | -$0.58 | Beat 14.71% | — |
| Aug 3, 2023 | -$0.65 | -$0.68 | Miss -4.62% | — |
| May 4, 2023 | -$0.69 | -$0.67 | Beat 2.90% | — |
| Mar 15, 2023 | -$0.67 | -$0.69 | Miss -2.99% | — |
| Aug 4, 2022 | -$0.99 | -$0.84 | Beat 15.15% | $859.0K |
| May 4, 2022 | -$0.67 | -$0.43 | Beat 35.82% | $25.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026